Introduction
Non-invasive ventilation (NIV) is an efficient treatment for patients with chronic hypercapnic respiratory failure (CRF) due to neuromuscular diseases, (NMD), restrictive thoracic disorders (RTD), obesity hypoventilation syndrome (OHS), and central hypoventilation syndromes (CHS). Regular assessment of the efficacy of ventilation is recommended, usually including a daytime sampling of arterial blood gases (ABG) and nocturnal pulse oximetry [1, 2] .
The importance of correcting daytime arterial CO 2 (PaCO 2 ) in patients treated with long term nocturnal NIV has recently been stressed [3e6] . ABG analysis is the gold standard for measuring PaCO 2 . However, ABG sampling requires expertise, can be painful and difficult to perform in patients with severe deformities or morbid obesity, and carries a risk of complications [7] . Furthermore ABG analysis is rarely available in sleep centres [8] or in patients' homes.
ABG analysis, although necessary, yields limited information. For instance, daytime ABG are poor predictors of nocturnal hypoventilation [9, 10] . Sampling of ABG during sleep may detect nocturnal hypoventilation, but will not reflect variations of PaCO 2 related to sleep stages, position or mask leaks. Nocturnal pulse oximetry, although useful and easy to perform, may underestimate nocturnal hypoventilation [8, 9, 11] , and it cannot discriminate nocturnal hypoventilation from other causes of hypoxaemia [2] .
Transcutaneous monitoring of carbon dioxide (PtcCO 2 ) allows non-invasive and continuous measurements of PaCO 2 . Although the accuracy of PtcCO 2 has been a subject of debate, PtcCO 2 monitors have become easier to use in clinical practice [12] and have shown acceptable agreement with PaCO 2 in a geriatric population [13] , in patients with acute dyspnoea [14] , patients with ALS [15] , patients with severe obesity [16] and during cardiopulmonary exercise testing [17] . Conversely, studies conducted at emergency departments [18, 19] , during surgery [20, 21] and in ICUs [20] report conflicting or poorer results, indicating that validity of PtcCO 2 may depend on the population studied and the clinical setting in which it is used. The small number of studies conducted in patients with CRF treated with NIV have either used older PtcCO 2 devices [22, 23] or included a limited number of patients [24e26] .
Although continuous PtcCO 2 measurement for 5e8 h is well tolerated, without causing cutaneous lesions, one concern is the overnight drift of the PtcCO 2 signal. Most studies addressing this issue include a limited number of patients, and both the methods used to measure the instrumental drift and the results differ considerably [22,23,25e30] . The uncertainty regarding PtcCO 2 drift is reflected in the conflicting recommendations regarding drift correction after nocturnal PtcCO 2 recordings [8, 31, 32] . This cumbersome procedure implies in vivo calibration with arterial or capillary blood gas sampling, adding discomfort for the patient and limiting its use in sleep centres and in patients' homes.
The present study was designed to determine 1) whether PtcCO 2 is a sufficiently accurate and precise tool for monitoring PaCO2 during routine follow-up visits in a large group of patients with CRF treated with long term NIV, and 2) if, in this setting, overnight drift of the PtcCO 2 sensor is clinically significant.
Materials and methods
The study protocol was approved by the Regional Committee for Medical and Health Research Ethics, NO ¼ 2012/1142. Written informed consent was obtained from all participants.
Patients
Patients with CRF due to NMD, RTD, OHS or CHS on long term NIV for a minimum of 3 months and scheduled for a regular followup visit were included. Exclusion criteria were: age below 18 years, inability to co-operate, hospitalization due to an acute exacerbation or change of NIV-treatment <3 months before inclusion.
Measurements
Daytime ABG sampling from the radial artery was performed after the patients had been seated and were breathing room air for at least 30 min and then immediately analysed (COBAS B 221, Roche, Germany). Daytime and overnight PtcCO 2 was measured with a TCM Tosca® with the Sensor 92 (Radiometer, Denmark) attached via a single-use ear clip to the patients' earlobe and probe temperature set at 43 C [33] . Auto-calibration, membrane replacement, temperature and metabolic correction were performed according to manufacturer's recommendations. Overnight PtcCO 2 signal was integrated to an online sleep recording system (Embletta Gold, Embla, Broomfield, USA). The PtcCO 2 sensor measures changes in pH produced by CO 2 diffusing through the skin to a buffer solution in the electrode. In order to measure the instrumental drift of the TCM Tosca capnograph, repeated ex vivo measurements of a calibration gas with a known CO 2 concentration were performed. The sensor was attached to a test unit containing the calibration gas and the PCO 2 was recorded. (Calibration Gas mixture for Blood Gas Analyzers, 11$2% CO 2 , balanced N 2, Radiometer, Denmark).
Study design
Patients were hospitalized for their regular NIV follow-up. Prior to daytime ABG sampling, performed between 12:00 and 2:00 PM, PtcCO 2 was monitored continuously for at least 22 min to allow stabilisation of PtcCO 2 readings, as recommended by the manufacturer. Daytime PtcCO 2 was defined as the PtcCO 2 value recorded 2 min after ABG sampling [28, 34] . The same sensor membrane was used during the night-time measurements. During overnight PtcCO 2 recordings, the signal quality was checked at least hourly. The instrumental drift was assessed by a repeated ex vivo calibration test. PCO 2 was measured using a gas mixture with a known CO 2 concentration. This procedure was performed at 11:00 PM after auto-calibration of the sensor, before attaching the sensor to the patient, and repeated at 7:00 AM before recalibration of the sensor. [20,25e27] . Paired sample ttests were used to determine if the instrumental drift was significantly different from zero. P-values below 0.05 were considered significant. SPSS Software for Windows and MedCalc version 14.10.2 were used for statistical analysis.
Statistics
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Results
All patients with long term NIV scheduled for a regular followup visit at the Department of Pulmonary Medicine of Oslo University Hospital Ullevål between April 2013 and May 2014 were evaluated: 95 patients met the inclusion criteria. Twenty-eight patients were not included (Fig. 1) . The remaining 67 patients were treated with NIV for OHS (n ¼ 16), NMD (n ¼ 36), CHS (n ¼ 5) or RTD (n ¼ 10). Main characteristics of patients are given in Table 1 . Mean PaCO 2 was 6$1 kPa (SD 0.9). Thirty-six (53%) of the patients were hypercapnic (PaCO 2 > 6.0 kPa), while none of the patients had a respiratory acidemia (pH < 7.3) and only 2 had a pH < 7.34. Agreement between PaCO 2 and PtcCO 2 in the sub-group of patients with a PaCO 2 > 6.0 kPa did not differ from that of the entire group; bias was 0.3 kPa, and limits of agreement were: À0.28; 0.84 kPa.
Instrumental drift of PtcCO 2
One patient disconnected the sensor prior to the morning measurement, and one recording showed an obvious technical error (morning PtcCO 2 : 15 kPa). Thus, 65 paired measurements were analysed.
In six patients there was an intermittent loss of PtcCO 2 signal during the night: in two patients the sensor fell off and had to be reconnected (one needed a new ear clip), and in four patients there was probably a temporary displacement of the sensor, which corrected itself without interference from the staff. None of these incidents required recalibration of sensor or change of membrane.
The mean drift of PtcCO 2 (difference between morning and evening PtcCO 2 readings of 11.2% CO 2 gas sample) was 0.14 ± 0.54 kPa/8 h (p ¼ 0.04; 95% CI: 0.01e0.27) (Fig. 3) . Of the 3 measurements showing a difference >1 kPa/8 h, 2 had a temporary loss of PtcCO 2 signal.
Discussion
To our knowledge, this is the first study to compare arterial with transcutaneous values of PCO 2 and to measure overnight instrumental drift of PtcCO 2 in a large group of patients treated with NIV for CRF. Our results show that daytime PaCO 2 values were strongly correlated with PtcCO 2 , over a wide range of PaCO 2 values, with a low bias and clinically acceptable limits of agreement. Importantly, none of the paired values of PaCO 2 e PtcCO 2 had a difference exceeding 1 kPa. Our data also show that PtcCO 2 can be used for overnight monitoring of NIV, most often without any clinically significant drift: overnight drift exceeded 1 kPa in 3 cases only. Finally, few problems related to the measurements occurred: one recording showed an obvious technical error, and 2 patients required reconnection of the sensor, without recalibration.
Bias (the mean of differences between PaCO 2 and PtcCO 2 ) was [20, 27, 36] . However, several studies using a probe T of 42 C showed similar results to ours [15e17, 25] , suggesting that other factors such as technical improvements in devices may also play an important role. Since our study did not compare different temperature settings and different sensors, we cannot quantify the importance of these factors. Previous studies of PtcCO 2 in patients with chronic hypoventilation most often included a limited number of patients, few non-COPD patients, and were conducted with older devices or during NIV. The only study of stable patients with chronic hypoventilation breathing spontaneously included 12 patients (6 non-COPD), and showed both a low bias and low limits of agreement [24] . However, accuracy decreased and limits of agreement increased with higher CO 2 -values (>7.3 kPa), a finding also described in other studies [22, 23] . In our data, accuracy and limits of agreements were unaffected by increasing levels of PaCO 2 . This discrepancy could be due to the low number of patients included or the devices assessed in the studies mentioned above [22e24]. Another study compared overnight PtcCO 2 with repeated ABG from an indwelling catheter in 15 patients: bias was low, but with wide limits of agreement [26] , probably caused by "outliers" amongst a low number of measurements. Our results are in agreement with an overnight study of 24 patients with CRF (9 non-COPD patients) by Storre et al., reporting a good agreement between capillary ABG and PtcCO 2 during NIV. In two of the three devices tested (Sentec DM and Tosca 500), discrepancies exceeding the clinically acceptable threshold of 1 kPa were rare (1e2% of the recordings). Bias was low and limits of agreement were unchanged in the sub-group of measurements with a PaCO 2 > 6.7 kPa [25] . A compilation of studies reporting on PtcCO 2 performance is summarized in Table 2 [37e53] (For details see Supplementary data).
ABG remain the gold standard for detecting daytime hypercapnia. However, our data suggest that PtcCO2 can be a valid substitute in hemodynamically stable patients, and prove to be particularly useful in settings were ABG sampling is difficult to perform, such as sleep clinics or home monitoring of long term mechanical ventilation. A critical requirement for obtaining reliable PtcCO 2 measurements is appropriate handling and knowledge of the equipment and procedure. Our team has long term experience with use of the PtcCO 2 device, probably contributing to the low number of technical problems encountered.
The second aim of the investigation was to study the instrumental drift of the PtcCO 2 sensor during overnight NIV-treatment. Mean drift was 0.02 kPa/hrs. Only one of the paired measurements showed an overnight drift exceeding 1.33 kPa, while three exceeded 1 kPa [27] . Thus, our study confirms that the vast majority of overnight PtcCO 2 recordings were performed without any clinically significant drift.
Instrumental drift during PtcCO 2 measurements has been evaluated using various methods (Table 2 ). In an 8 h sleep study of 6 stable ICU patients, change in bias over time was used as a measurement of drift [30] . PaCO 2 -PtcCO 2 difference increased linearly from 0.22 kPa to 0.72 kPa, suggesting an instrumental drift. Using the same methodology on a limited number of patients, 4 studies found lower levels of drift [16, 22, 23, 26] . Another study performed on 29 healthy individuals found no significant drift during continuous 4 h PtcCO 2 recordings [45] .
Two studies evaluated instrumental drift with a method similar to ours. Storre et al. calculated the total drift as the difference between 2 in vitro calibration measurements performed at the beginning of PtcCO 2 monitoring and after 4 h in 10 patients [28] , showing a significant drift of 0.17 kPa/h. Conversely, in an 8 hovernight study of 24 patients using three different devices (SenTec DM, Tosca 500 and TCM4 TINA), a low drift of PtcCO 2 was observed [25] . The results of this study, using modern devices, are in concordance with ours. Recent developments of PtcCO 2 devices may have contributed to improved results when compared to studies using older devices. Although newer devices still measure CO 2 by determining changes in pH of an electrolyte solution in the sensor separated from the skin by a permeable membrane, developments have been made both in the algorithm of the devices and the sensor [12] . For instance, modern algorithms allow automatic correction for the anaerobic factor and for the metabolic constant, and sensors are smaller and better protected. Overall, results of the current and other recent studies show good agreement between PtcCO 2 and PaCO 2 in patients with chronic hypoventilation, questioning the need for an initial in vivo calibration (i.e.: by ABG). In addition, the low instrumental drift diminishes the need for an in vivo or an ex vivo calibration at the end of an overnight monitoring. Thus, overnight monitoring of PtcCO 2 can be performed reliably in settings where ABG are not readily available, with a low percentage of erroneous readings.
A few problems related to the overnight measurements of PtcCO2 were observed. In one patient, an obvious technical error occurred. We did not observe any conflict between the interface banding (mask) and the PtcCO2 sensor connected to the earlobe. However displacement of the interface banding due to patient movement may have contributed to the intermittent loss of signal seen in 6 patients. If this problem occurs, an alternative location for the sensor could be a solution, preferably the upper chest [47] . An overnight drift of more than 1 kPa was observed in 3 patients. In 2 of these patients an intermittent loss of PtcCO 2 signal was observed.
Recalibration of the sensor after these incidents would probably have improved the results in these cases. Visual inspection of the overnight graphic display in addition to absolute values of PtcCO 2 could help the clinician in detecting these occasional events and in interpreting the results. Figs. 4e5 show examples of graphic displays of overnight PtcCO 2 . There are some limitations to our study. We only evaluated one of the commercially available PtcCO 2 devices and only one probe position i.e. the earlobe. Thus, the relevance of our findings is theoretically limited to this equipment and probe position. However, our results are similar to those presented by Storre et al. [25] using the Tosca 500 with a chest probe instead of an earlobe probe. The Tosca 500 uses an identical sensor, algorithm, and CO 2 detection method as the TCM Tosca. These authors also obtained similar results using the SenTec device [25] . The wider limits of agreement found using the TCM4 Tina may be due to the lower sensor temperature used [25] . Finally, Cuvelier et al. using the TCM3 Tina with the sensor temperature set to 44 C, reported similar bias and limits of agreement as in our study [24] .
Conclusions
In a large group of patients with a variety of diseases causing chronic hypercapnic respiratory failure, we found that the accuracy of transcutaneous measurement of CO 2 tension was acceptable for estimating PaCO 2 over a wide range of CO 2 levels. In addition, the overnight instrumental drift of the PtcCO 2 sensor was minor, questioning the necessity of systematic in vivo or ex vivo calibration. 
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